JP2024525613A5 - - Google Patents
Info
- Publication number
- JP2024525613A5 JP2024525613A5 JP2024500492A JP2024500492A JP2024525613A5 JP 2024525613 A5 JP2024525613 A5 JP 2024525613A5 JP 2024500492 A JP2024500492 A JP 2024500492A JP 2024500492 A JP2024500492 A JP 2024500492A JP 2024525613 A5 JP2024525613 A5 JP 2024525613A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- oligonucleotide
- optionally
- sequence
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163220016P | 2021-07-09 | 2021-07-09 | |
| US63/220,016 | 2021-07-09 | ||
| US202263316466P | 2022-03-04 | 2022-03-04 | |
| US63/316,466 | 2022-03-04 | ||
| PCT/US2022/073541 WO2023283624A2 (en) | 2021-07-09 | 2022-07-08 | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024525613A JP2024525613A (ja) | 2024-07-12 |
| JP2024525613A5 true JP2024525613A5 (enExample) | 2025-07-17 |
Family
ID=84802101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024500492A Pending JP2024525613A (ja) | 2021-07-09 | 2022-07-08 | 筋標的化複合体およびジストロフィノパチーを処置するためのその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240368296A1 (enExample) |
| EP (1) | EP4366741A4 (enExample) |
| JP (1) | JP2024525613A (enExample) |
| KR (1) | KR20240035824A (enExample) |
| AU (1) | AU2022309238A1 (enExample) |
| CA (1) | CA3226367A1 (enExample) |
| IL (1) | IL309912A (enExample) |
| MX (1) | MX2024000492A (enExample) |
| WO (1) | WO2023283624A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2021154477A1 (en) | 2020-01-31 | 2021-08-05 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2023283623A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| EP4702144A1 (en) | 2023-04-27 | 2026-03-04 | Sarepta Therapeutics, Inc. | Antisense oligomers for treatment of chronic kidney disease |
| WO2024233303A1 (en) * | 2023-05-05 | 2024-11-14 | Biomarin Pharmaceutical Inc. | Dystrophin exon skipping oligonucleotides |
| KR20260044219A (ko) | 2023-07-21 | 2026-04-01 | 매로우 테라퓨틱스, 인크. | 조혈 세포 표적화 접합체 및 관련 방법 |
| WO2025085810A2 (en) | 2023-10-18 | 2025-04-24 | Sarepta Therapeutics, Inc. | Antisense oligomers for treatment of centronuclear myopathies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004299053B2 (en) * | 2003-12-15 | 2011-01-06 | Alexion Pharmaceuticals, Inc. | Novel anti-DC-SIGN antibodies |
| ES2627917T3 (es) * | 2004-06-28 | 2017-08-01 | The University Of Western Australia | Oligonucleótidos no codificantes para la inducción de la omisión exónica y métodos de uso de los mismos |
| ZA200904022B (en) * | 2006-12-08 | 2010-08-25 | Lexicon Pharmaceuticals Inc | Monoclonal antibodies against ANGPTL3 |
| AU2011349443B2 (en) * | 2010-12-20 | 2015-12-24 | Genentech, Inc. | Anti-mesothelin antibodies and immunoconjugates |
| JP2014534806A (ja) * | 2011-08-23 | 2014-12-25 | ロシュ グリクアート アーゲー | 抗ｍｃｓｐ抗体 |
| JP2017513921A (ja) * | 2014-03-03 | 2017-06-01 | アーチャルジー、スジャータ | ジストロフィン異常症を治療するためのキメラジストロフィン−ｖｓｖ−ｇタンパク質 |
| AR099625A1 (es) * | 2014-03-21 | 2016-08-03 | Lilly Co Eli | Anticuerpos de il-21 |
| JP7015244B2 (ja) * | 2016-03-22 | 2022-02-02 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | プロテアーゼ活性化ｔ細胞二重特異性分子 |
| SG11202002517RA (en) * | 2017-09-22 | 2020-04-29 | Avidity Biosciences Inc | Nucleic acid-polypeptide compositions and methods of inducing exon skipping |
| WO2020028832A1 (en) * | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| AU2019315593B2 (en) * | 2018-08-02 | 2026-05-21 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof |
| WO2020219820A1 (en) * | 2019-04-25 | 2020-10-29 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| US20230111212A1 (en) * | 2020-01-10 | 2023-04-13 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| CN115427448A (zh) * | 2020-01-10 | 2022-12-02 | 达因疗法公司 | 肌肉靶向复合物及其用途 |
| MX2023000984A (es) * | 2020-07-23 | 2023-05-03 | Dyne Therapeutics Inc | Complejos dirigidos al musculo y usos de los mismos para el tratamiento de distrofinopatias. |
-
2022
- 2022-07-08 JP JP2024500492A patent/JP2024525613A/ja active Pending
- 2022-07-08 US US18/577,452 patent/US20240368296A1/en active Pending
- 2022-07-08 EP EP22838594.4A patent/EP4366741A4/en active Pending
- 2022-07-08 WO PCT/US2022/073541 patent/WO2023283624A2/en not_active Ceased
- 2022-07-08 IL IL309912A patent/IL309912A/en unknown
- 2022-07-08 CA CA3226367A patent/CA3226367A1/en active Pending
- 2022-07-08 AU AU2022309238A patent/AU2022309238A1/en active Pending
- 2022-07-08 KR KR1020247004338A patent/KR20240035824A/ko active Pending
- 2022-07-08 MX MX2024000492A patent/MX2024000492A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024525611A5 (enExample) | ||
| JP2024525612A5 (enExample) | ||
| JP2024527362A5 (enExample) | ||
| JP2024525610A5 (enExample) | ||
| IL309912A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309937A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309935A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309911A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309909A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| JP2023510350A5 (enExample) | ||
| JP2023535073A5 (enExample) | ||
| JP7803926B2 (ja) | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 | |
| US20240325558A1 (en) | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | |
| US11771776B2 (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| JP2024540199A (ja) | ジストロフィノパチーを処置するための筋標的化複合体 | |
| JP2023509793A5 (enExample) | ||
| JP2024540199A5 (enExample) | ||
| JP2024524222A5 (enExample) | ||
| JP2023512441A5 (enExample) | ||
| IL304048A (en) | Muscle targeting complexes and their uses for the treatment of myotonic dystrophy | |
| IL309936A (en) | Muscle targeting complexes and formulations for treating dystrophinopathies | |
| JP2024501872A5 (enExample) | ||
| JP2026503873A (ja) | Ｄｍｄ遺伝子のエクソン４５をスキップするための筋肉標的化複合体およびその使用 | |
| IL316143A (en) | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy | |
| IL316206A (en) | Dosage of muscle targeting complexes for the treatment of myotonic dystrophy |